Welcome to BioSeeker Group!

Analytical Tool - Cancer Therapeutic Antibodies

Additional Information

Published Date Sep 27, 2011
Format PDF & Software Application
Publisher BioSeeker Group

Availability: In stock

€3,949.00

Quick Overview

A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development.
Request free sample pages from Analytical Tool - Cancer Therapeutic Antibodies

"Analytical Tool - Cancer Therapeutic Antibodies" offers a unique tool for analyzing the vast amount of strategic possibilities that have emerged in antibody drug development for the treatment of cancer. It is at the same time a map of the research and development, a history of the achievements up to date, and a guide pointing out the directions of the future. The product as well, lays the framework of current treatment strategies and their progress. This tool provides you with an immense amount of information structured and analyzed to assist you in your work. It is designed to assist you in finding right partners, optimizing your licensing deals, wisely choosing which projects give you the best competitive advantage, and assuring you that your decisions have been based on the most accurate, validated and precise facts available.

Included in this advantageous package are two products already appreciated by many of our customers:


The Package Includes

  • A progress analysis on current and emerging drugs
  • Information on most companies active in antibody drug development in oncology
  • Information on key industry related antibody drug projects in oncology
  • Data from most important clinical trials
  • Information on early developmental stage projects
  • Possibility of performing advanced searches suited to your individual needs

This Tool will Assist You in:

  • Tracking cutting edge companies, therapies and new technologies
  • Rapid identification of partners & competitors
  • Laying down a comprehensive framework for further analysis of the field
  • Producing presentations surrounding the development of antibody drugs in oncology
  • Identifying emerging cancer antibody products & key areas of pharmaceutical R&D

*This software application is a searchable database reflects the most recent advances in the field of antibody drug development in cancer, in order to help you perform your own analysis, go back to the source data for in-depth information, and present the research and development in tables and graphs suited for your own specific purposes. A significant advantage with BioSeeker’s software applications is that they provide you with well-structured information. Each pipeline drug/project has been carefully defined and classified in categories and subcategories. The main categories include therapy type, effect, mechanism of action (molecular target), indication, stage of development etc. These categories are further organized and classified in sub-categories. In comparison with other available databases, BioSeeker’s software applications give better overview, specific search capabilities and great dynamic reports.

Request free sample pages from Analytical Tool - Cancer Therapeutic Antibodies

Other selected research from the 'Analytical Tool' category:


Analytical Tool - Lymphoma
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in lymphoma R&D and business development. Learn More


Analytical Tool - Colorectal Cancer
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in colorectal R&D and business development. Learn More

Other selected research from the 'Oncology' category:


IL-4 Signaling Pathway in Oncology Drug Pipeline Update 2011
There are today 128 companies plus partners developing 163 IL-4 pathway targeting drugs in 432 developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 61 drugs. Il-4 Signaling Pathway In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 94 different targets. Learn More


Triple Analysis: Breast Cancer, Colorectal Cancer and Angiogenesis
This triple analysis focuses on cancer drug development strategies in both Breast Cancer and Colorectal Cancer and by the mechanism/target/effect of Angiogenesis. Learn More

Other selected research from the 'Biologicals' category:


Peptides in Oncology Drug Pipeline Update 2011
There are today 217 (201) companies plus partners developing 218 (189) peptide drugs in 437 (346) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 108 (108) drugs. Peptides In Oncology Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 159 (149) different targets. Learn More


Biomarkers: Technological and Commercial Outlook 2011-2021
Discover the pharma and diagnostics opportunities there What are the commercial prospects for biomarkers in pharma and diagnostics? Our new report shows you commercial opportunities for biomarkers, predicting future trends... Learn More

Other selected research from the 'Immunomodulators' category:


Cancer Vaccines Drug Pipeline Update 2011
There are today 216 (195) companies plus partners developing 278 (209) cancer vaccine drugs in 500 (343) developmental projects in cancer. In addition, the accumulated number of ceased drugs over the last years amount to another 168 (173) drugs. Cancer Vaccines Drug Pipeline Update lists all drugs and gives you a progress analysis on each one of them. Identified drugs are linked to 110 (97) different targets. Learn More


Analytical Tool - Cancer Therapeutic Antibodies
A unique tool for analyzing the vast amount of strategic possibilities that have emerged in cancer antibody R&D and business development. Learn More